Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bph.15204 http://scihub22266oqcxt.onion/10.1111/bph.15204 32681537!7404855!32681537     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32681537.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Br+J+Pharmacol 2020 ; 177 (19): 4353-4374 Nephropedia Template TP {{tp|p=32681537|t=2020. Safety perspectives on presently considered drugs for the treatment of COVID-19 |pdf=|usr=}}{{32681537}} gab.com Text Safety perspectives on presently considered drugs for the treatment of COVID-19 JO: Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32681537 #FOAvip Intense efforts are underway to evaluate potential therapeutic agents for the treatment of COVID-19. In order to respond quickly to the crisis, the repurposing of existing drugs is the primary pharmacological strategy. Despite the urgent clinical need for these therapies, it is imperative to consider potential safety issues. This is important due to the harm-benefit ratios that may be encountered when treating COVID-19, which can depend on the stage of the disease, when therapy is administered and underlying clinical factors in individual patients. Treatments are currently being trialled for a range of scenarios from prophylaxis (where benefit must greatly exceed risk) to severe life-threatening disease (where a degree of potential risk may be tolerated if it is exceeded by the potential benefit). In this perspective, we have reviewed some of the most widely researched repurposed agents in order to identify potential safety considerations using existing information in the context of COVID-19. Twit Text FOAVip Safety perspectives on presently considered drugs for the treatment of COVID-19 ????Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32681537 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32681537 #FOAvip English Wikipedia <ref>{{Cite pmid|32681537}}</ref> Safety perspectives on presently considered drugs for the treatment of COVID-19 #MMPMID32681537 Penman SL; Kiy RT; Jensen RL; Beoku-Betts C; Alfirevic A; Back D; Khoo SH; Owen A; Pirmohamed M; Park BK; Meng X; Goldring CE; Chadwick AE Br J Pharmacol 2020[Oct]; 177 (19): 4353-4374 PMID32681537show ga Intense efforts are underway to evaluate potential therapeutic agents for the treatment of COVID-19. In order to respond quickly to the crisis, the repurposing of existing drugs is the primary pharmacological strategy. Despite the urgent clinical need for these therapies, it is imperative to consider potential safety issues. This is important due to the harm-benefit ratios that may be encountered when treating COVID-19, which can depend on the stage of the disease, when therapy is administered and underlying clinical factors in individual patients. Treatments are currently being trialled for a range of scenarios from prophylaxis (where benefit must greatly exceed risk) to severe life-threatening disease (where a degree of potential risk may be tolerated if it is exceeded by the potential benefit). In this perspective, we have reviewed some of the most widely researched repurposed agents in order to identify potential safety considerations using existing information in the context of COVID-19. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/*adverse effects/*therapeutic use[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Pandemics[MESH] |Risk Assessment[MESH]Safety perspectives on presently considered drugs for the treatment of(epmc).pdf DeepDyve Pubget Overpricing